Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

Immunocore Holdings plc

IMCR · Nasdaq · CIK 0001671927 · Healthcare · Biotechnology

INSIDER SIGNAL

No active buy signal

0 qualifying P purchase groups
in the current 180-day scoring window

0 Form 4 transaction lines observed in the same window
0 sales · 0 option, withholding, award, gift or other lines

Last qualifying purchase2025-03-17 · 667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP · $24.0M

WHY NO ACTIVE SIGNAL?

Purchase activityNone
Recent buyingNone
Recent salesNone
Buy signal statusInactive
Score anatomy

No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.

ClusterNot calculated
Purchase sizeNot calculated
RoleNot calculated
RecencyNot calculated
ConvictionNot calculated

Why is there no score?

  • No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
  • Sales and other Form 4 activity remain visible as context and do not create a negative score.

Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.

Insider activity timeline

No Form 4 transaction event is present in the current 180-day window.

Purchase breadth, concentration & cluster buying

These modules activate when qualifying purchases enter the 180-day research window.

SIGNAL HISTORY

No recorded active-signal snapshot

Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2025-03-17 · 667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP.

Recent Form 4 activity

0Purchases
10Sales
10Other Form 4 lines
7SEC filings · 365 days
BUYING0 qualifying P line(s) · 180 days
SELLING0 sale line(s) · context only
OTHER0 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context has not been captured for this ticker yet. The daily market-context job processes the US universe in rotating batches.

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
7,903,280
Previous report
7,770,242
Avg daily volume
381,726
Days to cover
20.7

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2025-03-17667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LPPurchase (P)American Depositary Shares807,338USD 29.72USD 23,992,063SEC filing ↗

Form 4 evidence

20 transaction lines in the latest 365-day window; 54 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-02-18St Leger Tina AmberSale (S)Ordinary Shares1,000USD 32.35USD 32,350SEC filing ↗
2026-02-18Jallal BahijaSale (S)Ordinary Shares11,474USD 32.35USD 371,184SEC filing ↗
2026-02-18GOLL JOHNSale (S)Ordinary Shares698USD 32.35USD 22,580SEC filing ↗
Show recent Form 4 evidence (20 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-02-18St Leger Tina AmberSale (S)Ordinary Shares1,000USD 32.35USD 32,350SEC filing ↗
2026-02-18Jallal BahijaSale (S)Ordinary Shares11,474USD 32.35USD 371,184SEC filing ↗
2026-02-18GOLL JOHNSale (S)Ordinary Shares698USD 32.35USD 22,580SEC filing ↗
2026-02-18Berman David MSale (S)Ordinary Shares5,965USD 32.35USD 192,968SEC filing ↗
2026-02-17St Leger Tina AmberOption exercise / conversion (M)Ordinary Shares2,119USD 0.00USD 0SEC filing ↗
2026-02-17Jallal BahijaOption exercise / conversion (M)Ordinary Shares23,817USD 0.00USD 0SEC filing ↗
2026-02-17GOLL JOHNOption exercise / conversion (M)Ordinary Shares1,351USD 0.00USD 0SEC filing ↗
2026-02-17Berman David MOption exercise / conversion (M)Ordinary Shares11,824USD 0.00USD 0SEC filing ↗
2025-12-05Berman David MSale (S)Ordinary Shares572USD 40.14USD 22,960SEC filing ↗
2025-12-05Berman David MOption exercise / conversion (M)Ordinary Shares572USD 17.46USD 9,987SEC filing ↗
2025-12-04Berman David MSale (S)Ordinary Shares31,341USD 40.26USD 1,261,789SEC filing ↗
2025-12-04Berman David MOption exercise / conversion (M)Ordinary Shares31,341USD 17.46USD 547,214SEC filing ↗
2025-11-28Berman David MSale (S)Ordinary Shares5,521USD 40.09USD 221,337SEC filing ↗
2025-11-28Berman David MOption exercise / conversion (M)Ordinary Shares5,521USD 17.46USD 96,397SEC filing ↗
2025-11-26Berman David MSale (S)Ordinary Shares69,404USD 40.12USD 2,784,488SEC filing ↗
2025-11-26Berman David MOption exercise / conversion (M)Ordinary Shares69,404USD 17.46USD 1,211,794SEC filing ↗
2025-11-25Berman David MSale (S)Ordinary Shares18,020USD 40.03USD 721,341SEC filing ↗
2025-11-25Berman David MOption exercise / conversion (M)Ordinary Shares18,020USD 17.46USD 314,629SEC filing ↗
2025-11-24Berman David MSale (S)Ordinary Shares100USD 40.00USD 4,000SEC filing ↗
2025-11-24Berman David MOption exercise / conversion (M)Ordinary Shares100USD 17.46USD 1,746SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerIMCR
CIK0001671927
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2836 Biological Products, (No Diagnostic Substances)
ExchangeNasdaq

Data coverage

Local Form 4 history54 transaction lines from 2024-01-03 to 2026-02-18
4 P purchase lines · 30 S sale lines · 20 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.